ArriVent BioPharma (AVBP) vs Inventiva S.A. American Depository Shares (IVA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
ArriVent BioPharma (AVBP) has outperformed Inventiva S.A. American Depository Shares (IVA) over the past year, losing 19.7% versus a loss of 38.1%. ArriVent BioPharma is the larger company by market cap ($823.9 million vs $784.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVBP | IVA |
|---|---|---|
| Share price | $16.71 | $3.32 |
| Market cap | $823.93M | $784.25M |
| 1-day change | -1.07% | -1.34% |
| YTD return | -16.95% | -28.60% |
| 1-year return | -19.74% | -38.06% |
| 5-year return | — | -75.22% |
| EPS (TTM) | $-3.62 | $-0.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $35.83 | $7.98 |
| 52-week low | $11.36 | $3.11 |
| Distance from 52-week high | -53.36% | -58.41% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +82.53% | +357.83% |
| Average volume | 908.55K | 1.39M |
| Shares outstanding | 49.31M | 236.22M |
| Employees | 77 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AVBP has outperformed IVA by 18.3 percentage points over the past year.
About ArriVent BioPharma
AVBP stock →ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 77 employees
About Inventiva S.A. American Depository Shares
IVA stock →Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
AVBP vs IVA FAQ
Which is bigger, ArriVent BioPharma or Inventiva S.A. American Depository Shares?
ArriVent BioPharma (AVBP) is larger, with a market capitalization of $823.93M compared with $784.25M for Inventiva S.A. American Depository Shares (IVA).
Which stock has performed better over the past year, AVBP or IVA?
AVBP returned -19.74% over the past 12 months, compared with -38.06% for IVA (price return, excluding dividends). Past performance does not predict future results.
Are ArriVent BioPharma and Inventiva S.A. American Depository Shares in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.